Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13435MR)

This product GTTS-WQ13435MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13435MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15486MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ4021MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ1014MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ15735MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ7576MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ15049MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ6679MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DMUC5754A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW